ArticleClinical rheumatology2025
Serological distribution of anti-endothelial cell antibodies and their association with laboratory indicators in autoimmune and immune-mediated diseases.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-endothelial cell antibodies (AECA) are implicated in vascular injury associated with autoimmune and inflammatory diseases. However, their distribution and clinical significance across diverse conditions remain inadequately characterized.
methodsWe analyzed 1,334 serum samples from patients with vasculitis, systemic autoimmune diseases, kidney diseases, arthritis, and other immune-mediated disorders. AECA titers were measured using indirect immunofluorescence assays and categorized as low (1:100), moderate (1:320) or high (1:1000). Laboratory parameters, including hematological, renal, hepatic, and coagulation indicators, were compared among different AECA titer groups within each disease category.
resultsAECA positivity was most frequently observed in vasculitis (40.6%), arthritis (44.4%), and autoimmune kidney diseases (25.5%). Higher titers were especially common in Behet's disease, ANCA-associated vasculitis, and ankylosing spondylitis. In autoimmune nephropathy, patients with moderate to high AECA titers (≥ 1:320) exhibited significantly elevated serum creatinine and urea levels compared to both AECA-negative and low-titer groups, suggesting impaired renal function. In the kidney disease subgroup, higher AECA titers indicated lower red blood cell counts and decreased estimated glomerular filtration rate (eGFR). Among systemic autoimmune diseases, moderate to high AECA titers were linked to significantly reduced white blood cell counts.
conclusionAECAs show heterogeneous distribution across immune-mediated diseases and are linked to laboratory abnormalities inidicative of endothelial injury and organ dysfunction. These findings support the potential role of AECA titier as biomarkers for systemic involvement, warranting validation in prospective studies. Key Points • Anti-endothelial cell antibodies (AECAs) are heterogeneously distributed across a broad spectrum of immune-mediated diseases. • AECA positivity is associated with disease-specific patterns, particularly in Behçet's disease and ANCA-associated vasculitis. • AECA may serve as potential serological biomarkers for disease severity and immune-mediated endothelial injury.
Indexed as
Identifiers
40986266What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.